Free Trial
NASDAQ:OVID

Ovid Therapeutics (OVID) Stock Price, News & Analysis

Ovid Therapeutics logo
$0.44 +0.01 (+1.72%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$0.45 +0.02 (+3.57%)
As of 06:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ovid Therapeutics Stock (NASDAQ:OVID)

Key Stats

Today's Range
$0.40
$0.46
50-Day Range
$0.28
$0.44
52-Week Range
$0.24
$1.47
Volume
1.54 million shs
Average Volume
446,031 shs
Market Capitalization
$31.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.13
Consensus Rating
Buy

Company Overview

Ovid Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

OVID MarketRank™: 

Ovid Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 161st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ovid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ovid Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Ovid Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ovid Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ovid Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ovid Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ovid Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.20% of the float of Ovid Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ovid Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ovid Therapeutics has recently increased by 50.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ovid Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Ovid Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.20% of the float of Ovid Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ovid Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ovid Therapeutics has recently increased by 50.60%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Ovid Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for OVID on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.10% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ovid Therapeutics' insider trading history.
Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Stock News Headlines

Ovid Therapeutics Inc. (OVID) - Yahoo Finance
Ovid Therapeutics Inc Chart - Morningstar
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

OVID Stock Analysis - Frequently Asked Questions

Ovid Therapeutics' stock was trading at $0.9337 at the start of the year. Since then, OVID shares have decreased by 53.2% and is now trading at $0.4374.

Ovid Therapeutics (NASDAQ:OVID) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.03 million. Ovid Therapeutics had a negative trailing twelve-month return on equity of 34.17% and a negative net margin of 4,562.23%.

Ovid Therapeutics (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Plug Power (PLUG), Alamos Gold (AGI), FuelCell Energy (FCEL), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Workhorse Group (WKHS).

Company Calendar

Last Earnings
5/13/2025
Today
7/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OVID
CIK
1636651
Fax
N/A
Employees
60
Year Founded
2014

Price Target and Rating

High Price Target
$4.00
Low Price Target
$1.50
Potential Upside/Downside
+614.4%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.43 million
Net Margins
-4,562.23%
Pretax Margin
-4,557.30%

Debt

Sales & Book Value

Annual Sales
$570 thousand
Price / Cash Flow
N/A
Book Value
$0.96 per share
Price / Book
0.46

Miscellaneous

Free Float
61,795,000
Market Cap
$31.10 million
Optionable
Optionable
Beta
0.13

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:OVID) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners